Literature DB >> 24594195

Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action.

Francesco Bedogni1, Riccardo L Rossi2, Francesco Galli3, Clementina Cobolli Gigli1, Anna Gandaglia1, Charlotte Kilstrup-Nielsen4, Nicoletta Landsberger5.   

Abstract

Rett syndrome (RTT) is a devastating genetic disorder that worldwide represents the most common genetic cause of severe intellectual disability in females. Most cases are caused by mutations in the X-linked MECP2 gene. Several recent studies have demonstrated that RTT mimicking animal models do not develop an irreversible condition and phenotypic rescue is possible. However, no cure for RTT has been identified so far, and patients are only given symptomatic and supportive treatments. The development of clinical applications imposes a more comprehensive knowledge of MeCP2 functional role(s) and their relevance for RTT pathobiology. Herein, we thoroughly survey the knowledge about MeCP2 structure and functions, highlighting the necessity of identifying more functional domains and the value of molecular genetics. Given that, in our opinion, RTT ultimately is generated by perturbations in gene transcription and so far no genes/pathways have been consistently linked to a dysfunctional MeCP2, we have used higher-level bioinformatic analyses to identify commonly deregulated mechanisms in MeCP2-defective samples. In this review we present our results and discuss the possible value of the utilized approach.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MeCP2; Molecular genetics; Pathway enrichment analysis; Perturbation in gene expression; Rett syndrome; Structure and function

Mesh:

Substances:

Year:  2014        PMID: 24594195     DOI: 10.1016/j.neubiorev.2014.01.011

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  21 in total

1.  Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders.

Authors:  Juanxian Cheng; Zhe Zhao; Liping Chen; Ying Li; Ruijing Du; Yan Wu; Qian Zhu; Ming Fan; Xiaotao Duan; Haitao Wu
Journal:  Neurosci Bull       Date:  2021-11-12       Impact factor: 5.203

2.  Diurnal variation in autonomic regulation among patients with genotyped Rett syndrome.

Authors:  Michael Sean Carroll; Jan-Marino Ramirez; Debra E Weese-Mayer
Journal:  J Med Genet       Date:  2020-03-10       Impact factor: 6.318

Review 3.  E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease.

Authors:  Lan-Hsin Wang; Nicholas E Baker
Journal:  Dev Cell       Date:  2015-11-09       Impact factor: 12.270

4.  Methyl-CpG binding protein 2 (MeCP2) localizes at the centrosome and is required for proper mitotic spindle organization.

Authors:  Anna Bergo; Marta Strollo; Marta Gai; Isabella Barbiero; Gilda Stefanelli; Sarah Sertic; Clementina Cobolli Gigli; Ferdinando Di Cunto; Charlotte Kilstrup-Nielsen; Nicoletta Landsberger
Journal:  J Biol Chem       Date:  2014-12-19       Impact factor: 5.157

5.  Mutations in JMJD1C are involved in Rett syndrome and intellectual disability.

Authors:  Mauricio A Sáez; Juana Fernández-Rodríguez; Catia Moutinho; Jose V Sanchez-Mut; Antonio Gomez; Enrique Vidal; Paolo Petazzi; Karolina Szczesna; Paula Lopez-Serra; Mario Lucariello; Patricia Lorden; Raul Delgado-Morales; Olga J de la Caridad; Dori Huertas; Josep L Gelpí; Modesto Orozco; Adriana López-Doriga; Montserrat Milà; Luís A Perez-Jurado; Mercedes Pineda; Judith Armstrong; Conxi Lázaro; Manel Esteller
Journal:  Genet Med       Date:  2015-07-16       Impact factor: 8.822

6.  Brain phosphorylation of MeCP2 at serine 164 is developmentally regulated and globally alters its chromatin association.

Authors:  Gilda Stefanelli; Anna Gandaglia; Mario Costa; Manjinder S Cheema; Daniele Di Marino; Isabella Barbiero; Charlotte Kilstrup-Nielsen; Juan Ausió; Nicoletta Landsberger
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

Review 7.  Epigenetic regulation of adult neural stem cells: implications for Alzheimer's disease.

Authors:  Carlos P Fitzsimons; Emma van Bodegraven; Marijn Schouten; Roy Lardenoije; Konstantinos Kompotis; Gunter Kenis; Mark van den Hurk; Marco P Boks; Caroline Biojone; Samia Joca; Harry W M Steinbusch; Katie Lunnon; Diego F Mastroeni; Jonathan Mill; Paul J Lucassen; Paul D Coleman; Daniel L A van den Hove; Bart P F Rutten
Journal:  Mol Neurodegener       Date:  2014-06-25       Impact factor: 14.195

Review 8.  MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis?

Authors:  Elisa Bellini; Giulio Pavesi; Isabella Barbiero; Anna Bergo; Chetan Chandola; Mohammad S Nawaz; Laura Rusconi; Gilda Stefanelli; Marta Strollo; Maria M Valente; Charlotte Kilstrup-Nielsen; Nicoletta Landsberger
Journal:  Front Cell Neurosci       Date:  2014-08-13       Impact factor: 5.505

9.  MeCP2 Related Studies Benefit from the Use of CD1 as Genetic Background.

Authors:  Clementina Cobolli Gigli; Linda Scaramuzza; Anna Gandaglia; Elisa Bellini; Marina Gabaglio; Daniela Parolaro; Charlotte Kilstrup-Nielsen; Nicoletta Landsberger; Francesco Bedogni
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

10.  Apoptotic Activity of MeCP2 Is Enhanced by C-Terminal Truncating Mutations.

Authors:  Alison A Williams; Vera J Mehler; Christina Mueller; Fernando Vonhoff; Robin White; Carsten Duch
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.